MedTrace Logo

Banlangen Granules Anti-seasonal Influenza Study

NCT02232945 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2016-03-04

No results posted yet for this study

Summary

This study aimed to evaluate the efficacy and safety of the nature herbal medicine Banlangen granules in patients infected with seasonal influenza A (H1N1,H3N2) and influenza B virus.

Conditions

Interventions

DRUG

placebo of oseltamivir phosphate

DRUG

oseltamivir phosphate

DRUG

Banlangen (Radix Isatidis) granules

DRUG

placebo of Banlangen(Radix Isatidis) granules

Sponsors & Collaborators

  • Guangzhou Institute of Respiratory Disease

    collaborator OTHER

  • Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited

    lead INDUSTRY

Principal Investigators

  • Nanshan Zhong, PhD · Guangzhou Institute of Respiratory Disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2016-08-31
Completion
2016-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02232945 on ClinicalTrials.gov